Seronegatives and Metabolic Abnormalities Protocol 2 (SAMA002): Study to Compare the Effect of Kaletra and Combivir® in HIV-Negative Healthy Subjects

HIV Infections Clinical Trial

Official title:

A 3 Arm, Prospective Study to Compare the Effect of 6 Weeks Exposure to the Combination of Lopinavir (LPVr)/Combivir® (AZT/3TC) Versus Lopinavir Alone or Combivir® Alone in HIV-negative Healthy Subjects on the Development of Abnormalities of Lipid and Glucose Metabolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00192621
• Other study ID #: SAMA 002 Version 5
• Secondary ID: ACTR012605000661
• Status: Completed
• Phase: Phase 4
• First received: September 12, 2005
• Last updated: April 11, 2012
• Start date: November 2004
• Est. completion date: December 2006

Study information

• Verified date: April 2012
• Source: Kirby Institute
• Contact: n/a
• Is FDA regulated: No
• Health authority: Australia: Department of Health and Ageing Therapeutic Goods Administration
• Study type: Interventional

Clinical Trial Summary

This is a randomised study of the effect of treatment with Combivir (zidovudine [AZT] and lamivudine [3TC]) and Kaletra (lopinavir [LPVr]), alone and in combination, on the development of abnormalities in lipid and glucose metabolism in HIV negative healthy subjects.

Description:

Antiretroviral medications, used to treat HIV infection, cause side effects. These include changes in the way that fat is laid down on the body. This results in fat loss from some parts of the body, with fat deposits at other sites, giving a characteristic look known as "HIV associated lipodystrophy" or HIVLD. With these changes, there are also abnormalities in glucose and fat metabolism (collectively termed metabolic abnormalities). In HIV negative populations, these metabolic changes are associated with an increased risk of developing cardiovascular disease (CVD). The aim of this study is to investigate if changes in the body's handling of fats and glucose occur with a short course of treatment in HIV negative subjects and if these correlate to an increased risk of CVD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: December 2006
• Est. primary completion date: December 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >18

• Be able to provide written consent to perform in the trial.

• HIV antibody negative and HIV DNA negative at time of entry to the study.

Exclusion Criteria:

• Any history of, or ongoing, mental or physical condition (including suspected or known diagnosis of ischaemic heart disease), which, in the opinion of the investigator, would impede the subject's ability to participate in the trial.

• History of type I or type II diabetes mellitus or previous treatment with antidiabetic medication.

• Prior use of testosterone, oestrogen, growth hormone or other oral glucocorticoid or anabolic steroid products within the previous six months.

• Alcohol or substance abuse which in the opinion of the investigator would affect the subject's ability to participate in the trial.

• Prior use of anti-retroviral agents (including protease inhibitors, nucleoside or non-nucleoside reverse transcriptase inhibitors, investigational antiretroviral agents or fusion inhibitors either in a previous study, as treatment or as part of post-exposure prophylaxis).

• Prior use of any retinoid-containing compound within the previous six months.

• Abnormal coagulation.

• Previous allergic reaction or known allergy to local anaesthetic.

• Previous use of psychotropic medications.

• Concomitant use of medications, including those metabolised by CYP3A4 enzyme system, which, in the opinion of the investigator, would affect the subject's ability to participate in all activities involved in the trial.

• Any grade-three laboratory abnormality recorded from screening bloods.

• Any grade-two laboratory abnormality recorded from screening bloods, which, in the opinion of the investigator, would impede the subject's ability to safely complete all study requirements.

• Gastrointestinal disorders, which may affect drug absorption.

• Any finding on screening clinical examination, which, in the opinion of the investigator, would impede the subject's ability to participate in the rest of the trial.

• Pregnancy

• Evidence of acute or chronic active hepatitis B virus infection by serology performed at baseline.

• Evidence of hepatitis C infection by serology performed at baseline.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Cardiovascular Disease
• Cardiovascular Diseases
• Congenital Abnormalities
• Dyslipidemias
• Glucose Metabolism Disorders
• HIV Infections
• Lipodystrophy
• Metabolic Diseases

Intervention

Drug:
• Combivir (zidovudine [AZT] / lamivudine [3TC])

• Kaletra (lopinavir [LPVr])

Locations

Country	Name	City	State
Australia	St Vincents Hospital	Sydney	New South Wales

Sponsors (5)

Lead Sponsor	Collaborator
Kirby Institute	Garvan Institute of Medical Research, National Heart, Lung, and Blood Institute (NHLBI), Prince of Wales Hospital, Sydney, St Vincent's Hospital, Sydney

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine effect of 6 wks ART with LPVr and CBV, alone and in combination, in HIV negative healthy subjects with respect to changes from baseline in genes related to mitochondrial and lipid metabolism in adipocytes
Secondary	includes: To determine the effect of 6 wks of ART with LPVr and CBV in HIV negative subjects with respect to: changes from baseline in genes related to mitochondrial and lipid and glucose metabolism in monocytes.

External Links

•   National Centre in HIV Epidemiology and Clinical Research Homepage